Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy.Pan, P., Knudson, S.E., Bommineni, G.R., Li, H.J., Lai, C.T., Liu, N., Garcia-Diaz, M., Simmerling, C., Patil, S.S., Slayden, R.A., Tonge, P.J.
(2014) Chemmedchem 9: 776-791
- PubMed: 24616444
- DOI: 10.1002/cmdc.201300429
- PubMed Abstract:
- A Structural and energetic model for the slow-onset inhibition of InhA, an enzyme drug target from Mycobacterium tuberculosis
Li, H.J.,Lai, C.T.,Pan, P.,Yu, W.,Liu, N.,Garcia-Diaz, M.,Simmerling, C.,Tonge, P.J.
() TO BE PUBLISHED --: --
The diaryl ethers are a novel class of antituberculosis drug candidates that inhibit InhA, the enoyl-ACP reductase involved in the fatty acid biosynthesis (FASII) pathway, and have antibacterial activity against both drug-sensitive and drug-resistant ...
The diaryl ethers are a novel class of antituberculosis drug candidates that inhibit InhA, the enoyl-ACP reductase involved in the fatty acid biosynthesis (FASII) pathway, and have antibacterial activity against both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. In the present work, we demonstrate that two time-dependent B-ring modified diaryl ether InhA inhibitors have antibacterial activity in a mouse model of TB infection when delivered by intraperitoneal injection. We propose that the efficacy of these compounds is related to their residence time on the enzyme, and to identify structural features that modulate drug-target residence time in this system, we have explored the inhibition of InhA by a series of B-ring modified analogues. Seven ortho-substituted compounds were found to be time-dependent inhibitors of InhA, where the slow step leading to the final enzyme-inhibitor complex (EI*) is thought to correlate with closure and ordering of the InhA substrate binding loop. A detailed mechanistic understanding of the molecular basis for residence time in this system will facilitate the development of InhA inhibitors with improved in vivo activity.
Institute for Chemical Biology & Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400 (USA).